

ICH E3 Guideline Section Number and Title	CORE Reference Section Number and Title
1 Title Page	1 Title Page
2 Synopsis	2 Synopsis
3 Table of Contents for the Individual Clinical Study Report	3 Table of Contents
4 List of Abbreviations and Definition of Terms	4 List of Abbreviations and Definition of Terms
5 Ethics	5 Ethics
5.1 Independent Ethics Committee (IEC) or Institutional Review Board (IRB)	5.1 Independent Ethics Committee and/or Institutional Review Board
5.2 Ethical Conduct of the Study	5.2 Ethical Conduct of the Study
5.3 Patient Information and Consent	5.3 Subject Information and Consent
6 Investigators and Study Administrative Structure	6 Investigators and Study Administrative Structure
7 Introduction	7 Introduction
8 Study Objectives	8 Study Objectives and Endpoints 8.1 Objectives 8.2 Endpoints
9 Investigational Plan	9 Investigational Plan
9.1 Overall Study Design and Plan - Description	9.1 Overall Study Design and Plan
9.2 Discussion of Study Design, Including the Choice of Control Groups	9.2 Discussion of Study Design, Including the Choice of Control Groups
9.3 Selection of Study Population	9.3 Selection of Study Population
9.3.1 Inclusion Criteria	9.3.1 Inclusion Criteria
9.3.2 Exclusion Criteria	9.3.2 Exclusion Criteria
9.3.3 Removal of Patients from Therapy or Assessment	9.3.3 Removal of Subjects from Therapy or Assessment
9.4 Treatments	9.4 Treatment
9.4.1 Treatments Administered	9.4.1 Treatments Administered 9.4.1.1 Investigational Product(s) 9.4.1.2 Non-investigational Product(s)
9.4.2 Identity of Investigational Product(s)	9.4.2 Identity of Investigational Product(s)
9.4.3 Method of Assigning Patients to Treatment Groups	9.4.3.1 Methods of Assigning of Subjects to Treatment Groups
9.4.4 Selection of Doses in the Study	9.4.4 Selection of Dose(s) and Timing of Dose for Each Subject
9.4.5 Selection and Timing of Dose for each Patient	9.4.4 Selection of Dose(s) and Timing of Dose for Each Subject
9.4.6 Blinding	9.4.3.2 Blinding and Unblinding
9.4.7 Prior and Concomitant Therapy	9.4.6 Prior and Concomitant Therapy
9.4.8 Treatment Compliance	9.4.5 Treatment Compliance
9.5 Efficacy and Safety Variables	9.5 Efficacy and Safety Variables
9.5.1 Efficacy and Safety Measurements Assessed and Flow Chart	9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments 9.5.1.4 Safety – Adverse Events 9.5.1.5 Safety – Clinical Laboratory Evaluation 9.5.1.6 Safety – Vital Sign Measurements 9.5.1.7 Safety – Physical Examination 9.5.3 Pharmacokinetic and Pharmacodynamic Measurements 9.5.3.2 Pharmacokinetic Parameters 9.5.3.3 Pharmacodynamic Measurements 9.5.3.4 Pharmacodynamic Parameters 9.5.4 Other Measurements
9.5.2 Appropriateness of Measurements	9.5.2 Appropriateness of Measurements
9.5.3 Primary Efficacy Variable(s)	9.5.1.1 Primary Efficacy Measurement
9.5.4 Drug Concentration Measurements	9.5.3.1 Pharmacokinetic Measurements
9.6 Data quality assurance	9.6 Data Quality Assurance
9.7 Statistical Methods Planned in the Protocol and Determination of Sample Size	9.7 Statistical Analysis Methods Planned in the Protocol and Determination of Sample Size
9.7.1 Statistical and Analytical Plans	9.7.1 Statistical Plans 9.7.1.1 General Approaches 9.7.1.2 Primary Efficacy Endpoint Methodology 9.7.1.3 Secondary Efficacy Endpoint Methodology 9.7.1.4 Other Efficacy Endpoint Methodology 9.7.1.5 Safety Endpoint Methodology 9.7.1.6 Pharmacokinetic and Pharmacodynamic Endpoints Methodology 9.7.1.7 Other Endpoint Methodology
9.7.2 Determination of Sample Size	9.7.2 Determination of Sample Size
9.8 Changes in the Conduct of the Study or Planned Analyses	9.8 Changes in the Conduct of the Study or Planned Analyses 9.8.1 Changes in the Conduct of the Study 9.8.2 Changes in the Planned Analyses 9.8.3 Changes Following Study Unblinding and Post-hoc Analyses
10 Patients	10 Study Subjects
10.1 Disposition of Patients	10.1 Disposition of Subjects
10.2 Protocol Deviations	10.2 Protocol Deviations
11 Efficacy Evaluation	11 Efficacy and Other Evaluations
11.1 Data Sets Analysed	10.3 Data Sets Analysed

ICH E3 Guideline Section Number and Title	CORE Reference Section Number and Title
11.2 Demographic and Other Baseline Characteristics	10.4 Demographic and Other Baseline Characteristics 10.4.1 Demography 10.4.2 Baseline Disease Characteristics 10.4.3 Medical History and Concurrent Illnesses 10.4.4 Prior and Concomitant Treatments
11.3 Measurements of Treatment Compliance	10.5 Measurements of Treatment Compliance
11.4 Efficacy Results and Tabulations of Individual Patient Data	11.1 Efficacy Results
11.4.1 Analysis of Efficacy	11.1.1 Primary Efficacy Endpoint 11.1.2 Secondary Efficacy Endpoints 11.1.3 Other Efficacy Endpoints 11.1.4 Post-hoc Analyses
11.4.2 Statistical/Analytical Issues	11.2 Results of Statistical Issues Encountered During the Analysis
11.4.2.1 Adjustments for Covariates	11.2.1 Adjustments for Covariates
11.4.2.2 Handling of Dropouts or Missing Data	11.2.2 Handling of Withdrawals, Discontinuations or Missing Data
11.4.2.3 Interim Analyses and Data Monitoring	11.2.3 Interim Analyses and Data Monitoring
11.4.2.4 Multicentre Studies	11.2.4 Multicentre Studies
11.4.2.5 Multiple Comparison/Multiplicity	11.2.5 Multiple Comparison/Multiplicity
11.4.2.6 Use of an "Efficacy Subset" of Patients	11.2.6 Use of an "Efficacy Subset" of Subjects
11.4.2.7 Active-Control Studies Intended to Show Equivalence	11.1 Efficacy Results
11.4.2.8 Examination of Subgroups	11.2.7 Examination of Subgroups
11.4.3 Tabulation of Individual Response Data	11.2.8 Tabulation of Individual Response Data
11.4.4 Drug Dose, Drug Concentration, and Relationships to Response	11.3.1 Drug Dose, Drug Concentration and Relationships to Response
11.4.5 Drug-Drug and Drug-Disease Interactions	11.3.2 Drug-Drug and Drug-Disease Interactions
11.4.6 By-Patient Displays	NOT INCLUDED
11.4.7 Efficacy Conclusions	11.4 Efficacy Results Summary
12 Safety Evaluation	12 Safety Evaluation
12.1 Extent of Exposure	10.6 Extent of Exposure
12.2 Adverse Events (AEs)	12.1 Adverse Events
12.2.1 Brief Summary of Adverse Events	12.1.1 Brief Summary of Adverse Events
12.2.2 Display of Adverse Events	12.1.2 Most Frequently Reported Adverse Events
12.2.3 Analysis of Adverse Events	12.1.2 Most Frequently Reported Adverse Events 12.1.3 Categorisation of All Adverse Events
12.2.4 Listing of Adverse Events by Patient	NOT INCLUDED
12.3 Deaths, Other Serious Adverse Events, and Other Significant Adverse Events	12.2 Analysis of Deaths, Other Serious Adverse Events, and Other Clinically Meaningful Adverse Events
12.3.1 Listing of Deaths, other Serious Adverse Events and Other Significant Adverse Events	12.2.1 Deaths, Other Serious Adverse Events, Discontinuations due to Adverse Events and Other Adverse Events of Special Interest
12.3.1.1 Deaths	12.2.1.1 Deaths
12.3.1.2 Other Serious Adverse Events	12.2.1.2 Other Serious Adverse Events
12.3.1.3 Other Significant Adverse Events	12.2.1.3 Discontinuations Due to Adverse Events 12.2.1.4 Other Adverse Events of Special Interest
12.3.2 Narratives of Deaths, Other Serious Adverse Events and Certain Other Significant Adverse Events	12.2.2 Narratives of Deaths, Other Serious Adverse Events, and Certain Other Clinically Meaningful Adverse Events
12.3.3 Analysis and Discussion of Deaths, Other Serious Adverse Events and Other Significant Adverse Events	12.2.1 Deaths, Other Serious Adverse Events, Discontinuations due to Adverse Events and Other Adverse Events of Special Interest
12.4 Clinical Laboratory Evaluation	12.3 Clinical Laboratory Evaluation
12.4.1 Listing of Individual Laboratory Measurements by Patient (16.2.8) and Each Abnormal Laboratory Value (14.3.4)	12.3.1 Individual Laboratory Measurements by Subject and Abnormal Laboratory Values
12.4.2 Evaluation of Each Laboratory Parameter	12.3.2 Evaluation of Laboratory Values
12.4.2.1 Laboratory Values Over Time	12.3.2.1 Laboratory Values Over Time
12.4.2.2 Individual Patient Changes	12.3.2.2 Individual Subject Changes in Laboratory Values
12.4.2.3 Individual Clinically Significant Abnormalities	12.3.2.3 Individual Clinically Meaningful Laboratory Abnormalities
12.5 Vital Signs, Physical Findings and Other Observations Related to Safety	12.4 Vital Signs, Physical Examinations, and Other Observations Related to Safety 12.4.1 Vital Signs 12.4.2 Physical Examination Findings 12.4.3 Other Observations Related To Safety
12.6 Safety Conclusions	12.5 Safety Results Summary
13 Discussion and Overall Conclusions	13 Discussion and Overall Conclusions 13.1 Discussion 13.2 Conclusions
14 Tables, Figures and Graphs Referred to But Not Included in the Text	14 Tables and Figures
14.1 Demographic Data	14.1 Demographic Data
14.2 Efficacy Data	14.2 Efficacy Data
14.3 Safety Data	14.3 Safety Data
14.3.1 Displays of Adverse Events	14.3.1 Displays of Adverse Events
14.3.2 Listings of Deaths, Other Serious and Significant Adverse Events	14.3.2 Listing of Deaths, Other Serious and Clinically Meaningful Adverse Events

ICH E3 Guideline Section Number and Title	CORE Reference Section Number and Title
14.3.3 Narratives of Deaths, Other Serious and Certain Other Significant Adverse Events	14.3.3 Narratives of Deaths, Other Serious Adverse Events and Certain Other Clinically Meaningful Adverse Events
14.3.4 Abnormal Laboratory Value Listing (Each Patient)	14.3.4 Data Listings (Each Subject) for Abnormal Clinically Meaningful Laboratory Values, Vital Signs, Physical Examinations and Other Observations Related to Safety
15 Reference List	15 Reference List
16 Appendices	16 Appendices
16.1 Study Information	16.1 Study Information
16.1.1 Protocol and protocol amendments	16.1.1 Protocol and protocol amendments
16.1.2 Sample case report form (unique pages only)	16.1.2 Sample case report form (may include unique pages only)
16.1.3 List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority) - Representative written information for patient and sample consent forms	16.1.3 List of IECs or IRBs (plus the name of the committee Chair if required by the regulatory authority)
16.1.4 List and description of investigators and other important participants in the study, including brief (1 page) CVs or equivalent summaries of training and experience relevant to the performance of the clinical study	16.1.4 List and description of Investigators and other important participants in the study
16.1.5 Signatures of principal or coordinating investigator(s) or sponsor's responsible medical officer, depending on the regulatory authority's requirement	16.1.5 Signatures of Principal (for single-centre studies) or Coordinating Investigator(s) (for multi-centre studies) and/or Sponsor's responsible medical officer (depending on the Regulatory Authority's requirement) and signature of responsible biostatistician
16.1.6 Listing of patients receiving test drug(s)/investigational product(s) from specific batches, where more than one batch was used	16.1.6 List of Investigational Product(s) batch numbers
16.1.7 Randomisation scheme and codes (patient identification and treatment assigned)	16.1.7 Randomisation scheme and codes (subject identification and treatment assigned)
16.1.8 Audit certificates (if available) (see Annex IVa and IVb of the guideline)	16.1.8 Audit certificates (if necessary [region and/or country-specific], and if available)
16.1.9 Documentation of statistical methods	16.1.9 Documentation of statistical methods
16.1.10 Documentation of inter-laboratory standardisation methods and quality assurance procedures if used	16.1.10 Documentation of inter-laboratory standardisation methods and laboratory QA procedures if used (depending on the Regulatory Authority's requirement)
16.1.11 Publications based on the study	16.1.11 Publications based on study
16.1.12 Important publications referenced in the report	16.1.12 Important publications referenced in the report
16.2 Patient Data Listings	16.2 Subject Data Listings
16.2.1 Discontinued patients	16.2.1 Discontinued Subjects
16.2.2 Protocol deviations	16.2.2 Protocol Deviations
16.2.3 Patients excluded from the efficacy analysis	16.2.3 Subjects Excluded from the Efficacy Analysis
16.2.4 Demographic data	16.2.4 Demographic Data
16.2.5 Compliance and/or drug concentration data (if available)	16.2.5 Compliance and/or Drug Concentration Data (if available)
16.2.6 Individual efficacy response data	16.2.6 Individual Efficacy Response Data
16.2.7 Adverse event listings (each patient)	16.2.7 Adverse Event Listings (each Subject)
16.2.8 Listing of individual laboratory measurements by patient, when required by regulatory authorities	16.2.8 Listing of Individual Laboratory Measurements by Subject When Required by Regulatory Authorities
16.3 Case Report Forms	16.3 Case Report Forms
16.3.1 CRFs for deaths, other serious adverse events and withdrawals for AE	16.3.1 CRFs for deaths, other SAEs and withdrawals for AE
16.3.2 Other CRFs submitted	16.3.2 Other CRFs submitted (only if applicable)
16.4 Individual Patient Data Listings (US Archival Listings)	16.4 Individual Subject Data Listings (US archival listings)
ANNEX I Synopsis (Example)	NOT INCLUDED - Example synopsis table is included in Section 2 (Synopsis) of the CORE Reference (so Annex I Synopsis is removed from annexes)
ANNEX II Principal or Coordinating Investigator(s) Signature(s) or Sponsor's Responsible Medical Officer (Example)	ANNEX I (Appendix 16.1.5) Principal or Coordinating Investigator(s) Signature(s) (and/or Sponsor's Responsible Medical Officer Signature and Statistician's Signature)
ANNEX IIIa Study Design and Schedule of Assessments (Example)	NOT INCLUDED - Example Table 9.1 (9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments) in the CORE Reference is derived from Annexes IIIa and IIIb (which are therefore removed from the annexes)
ANNEX IIIb Study Design and Schedule of Assessments (Example)	NOT INCLUDED - Example Table 9.1 (9.5.1 Efficacy and Safety Measurements Assessed and Schedule of Assessments) in the CORE Reference is derived from Annexes IIIa and IIIb (which are therefore removed from the annexes)
ANNEX IVa Disposition of Patients (Example)	NOT INCLUDED - Example Figure 10.1 in the CORE Reference (Section 10.1 Disposition of Patients) is derived and amended from Annexes IVa and IVb (which are therefore removed from annexes)
ANNEX IVb Disposition of Patients (Example)	NOT INCLUDED - Example Figure 10.1 in the CORE Reference (Section 10.1 Disposition of Patients) is derived and amended from Annexes IVa and IVb (which are therefore removed from annexes)

ICH E3 Guideline Section Number and Title	CORE Reference Section Number and Title
ANNEX V Listing of Patients Who Discontinued Therapy (Example)	ANNEX II (Appendix 16.2.1) Listing of Subjects Who Discontinued Treatment (Data Set Identification)
ANNEX VI Listing of Patients and Observations Excluded from Efficacy Analysis	ANNEX III (Appendix 16.2.3) Listing of Subjects and Observations Excluded from the Efficacy Analysis
ANNEX VII Number of Patients Excluded from Efficacy Analysis (Example)	NOT INCLUDED - Example Table 10.2 in the CORE Reference (Section 10.2 Protocol Deviations) is derived and amended from Annex VII (which is therefore removed from annexes)
ANNEX VIII Guidance for Section 11.4.2 – Statistical/Analytical Issues and Appendix 16.1.9	ANNEX IV Guidance for Sections 9.7 and 11.2 - Statistical Issues and Appendix 16.1.9
<p data-bbox="49 533 97 555">New</p>	<p data-bbox="796 360 1182 383">9.3.4 Stopping or Suspending the Study</p> <p data-bbox="796 394 1023 416">9.4.3 Avoidance of Bias</p> <p data-bbox="796 427 1203 450">9.5.1.2 Secondary Efficacy Measurements</p> <p data-bbox="796 461 1158 483">9.5.1.3 Other Efficacy Measurements</p> <p data-bbox="796 495 1469 517">11.3 Pharmacokinetic, Pharmacodynamic and Other Analyses Results</p> <p data-bbox="796 528 1023 551">11.3.3 Other Endpoints</p> <p data-bbox="796 562 954 584">14.4 Other Data</p> <p data-bbox="796 595 1378 618">16.1.13 Optional Appendix e.g. Data Monitoring Committee</p> <p data-bbox="796 629 1506 651">ANNEX V (Appendix 16.2.7) Adverse Events: Number Observed and Rate, With Subject Identifications</p> <p data-bbox="796 663 1514 685">ANNEX VI (all measurements in Listing 16.2.8; abnormal measurements in Listing 14.3.3)</p>